BeiGene Ltd is a clinical-stage biopharmaceutical company engaged in the discovery & development of molecularly targeted & immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-283 and BGB-290 and one immuno-oncology agent. This is an ADR of a company whose stock trades outside of the U.S. as the symbol HK:6160.

$166.99  +5.14 (3.18%)
As of 07/01/2022 15:59:58 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  China
Country of incorporation:  
IPO date:  02/03/2016
Outstanding shares:  103,277,246
Average volume:  326,701
Market cap:   $16,760,864,253
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BYYWPW6
Valuation   (See tab for details)
PE ratio:   -8.73
PB ratio:   2.82
PS ratio:   19.11
Return on equity:   -32.52%
Net income %:   -218.25%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy